EGFR and neoplasm: This theory may explain why a ten-fold reduction in EGFR affinity of nimotuzumab compared to cetuximab leads to selective binding in tumor tissue while sparing healthy tissues, thereby reducing adverse effects (Garrido et al., 2011).